4 results about "Pyrazinamide" patented technology

The invention discloses a novel compound preparation for resisting mycobacterium tuberculosis and a preparation method thereof.The compound preparation comprises glutathione active part and pyrazinamide, the weight ratio of glutathione to pyrazinamide is (2-4): 5, the glutathione active part comprises glutathione, an isolation stabilizer, a plasticizer, an anti-sticking agent and a first stabilizer, and the first stabilizer comprises glutathione, an isolation stabilizer, a plasticizer, an anti-sticking agent and a second stabilizer. According to the glutathione active part, firstly, a fluidized powder coating technology is adopted, and the relatively unstable active ingredient glutathione is subjected to powder coating; and preparing the coated components, pyrazinamide, a filler, a second stabilizer, an adhesive, a disintegrating agent and a lubricant into a specific preparation. According to the preparation, the hepatotoxicity during pyrazinamide medication is reduced, the compliance is increased, and meanwhile, the technical problem that a pyrazinamide glutathione preparation is unstable is solved.

The invention relates to a method for determining the sensitivity of a mycobacterium tuberculosis strain to pyrazinamide. The method comprises the following steps: (i) determining whether at least one mutation exists in the rpoB gene between 761112 and 761182 in the genome of the strain; and (ii) determining the sensitivity or drug resistance property of the strain according to the presence or absence of the at least one mutation. The invention also relates to a kit comprising a means for detecting at least one sequence selected from SEQ ID NO: 1-3; the invention also relates to application of the kit in determining the sensitivity of the mycobacterium tuberculosis strain to pyrazinamide.

The present invention relates to a fusion polypeptide derived from Toxoplasma gondii. The fusion polypeptide can be used as a pharmaceutical composition for treating tuberculosis. In particular, the fusion polypeptide according to the present invention acts specifically on the lungs infected with Mycobacterium tuberculosis and has therapeutic efficacy even against tuberculosis having resistance to isoniazid (INH), pyrazinamide (PZA), rifampin (RFP), and / or streptomycin (SM).

The application discloses a kind of drug combination and its application.The application provides a kind of drug combination or pharmaceutical composition, the active component of the drug combination or pharmaceutical composition includes material A, material B, material C and material D;Material A is compound I or its pharmaceutically acceptable salt;Material B is isoniazid (H) or its pharmaceutically acceptable salt;Material C is rifampicin (R) or its pharmaceutically acceptable salt;Material D is pyrazinamide (Z) or its pharmaceutically acceptable salt.The drug combination or pharmaceutical composition of the application can reduce alveolar inflammation, pulmonary tuberculosis inflammatory lung injury and pulmonary tuberculosis secondary fibrosis, while increasing the penetration of anti-tuberculosis drugs in the lesion site, to accelerate the treatment response, reduce the risk of recurrence.